Teva, Allergan Probably Won't Need More Divestments To Get FTC Approval
Executive Summary
Parties have already agreed to sell more than 50 products so far, but are still extending outside date for closing of Teva's acquisition of Allergan's generic business until October.
You may also be interested in...
Teva, Allergan Generics: FTC Worried About A Multitude Of Markets, Not A Behemoth
Record-setting divestment order driven by sheer number of products where firms competed, not size of company that would result from acquisition.
PhRMA Embraces Teva Across Brand-Generic Divide
PhRMA accepts Teva's request for membership; BIO rejected Teva five years ago.
Teva’s Rosy View For A Happy Union With Allergan Generics
The company provided updated mid-term guidance for the combined company, net revenues of $26.7bn to $27.8bn and EBITDA of $10.7bn to $11.5bn in 2019. The deal is expected to close any day, management assured investors.